Evidence map›Paper›PMID 33573015›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Monitoring of Peripheral Blood Leukocytes and Plasma Samples: A Pilot Study to Examine Treatment Response to Leflunomide in Rheumatoid Arthritis.

João F S Rodrigues, Liziane C M da Silva, Leia Cardoso-Sousa, Douglas Carvalho Caixeta, Debora D Lückemeyer, Alisson S Henrique, Jaqueline P Pontes, Lycia M G da Silva, Juliana S S Macedo, Pedro S Carvalho Júnior and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

João F S RodriguesPrograma de Pós-Graduação, Universidade CEUMA, São Luís 65075-120, Brazil.
Liziane C M da SilvaInstituto de Pesquisa Pelé Pequeno Príncipe, Curitiba 80250-060, Brazil.
Leia Cardoso-SousaInstituto de Ciências Biomédicas, Universidade Federal de Uberlândia, Uberlândia 38400-902, Brazil.
Douglas Carvalho CaixetaInstituto de Ciências Biomédicas, Universidade Federal de Uberlândia, Uberlândia 38400-902, Brazil.
Debora D LückemeyerDepartamento de Farmacologia, Universidade Federal de Santa Catarina, Florianópolis 88040-900, Brazil.ORCID 0000-0002-2231-6511
Alisson S HenriqueMestrado em Computação Aplicada, Universidade do Vale do Itajaí, Itajaí, São José 88102-700, Brazil.ORCID 0000-0002-0584-9746
Jaqueline P PontesPrograma de Pós-Graduação em Ciências da Saúde, Universidade Federal do Maranhão, São Luís 65080-805, Brazil.
Lycia M G da SilvaFarmácia Estadual de Medicamentos Especializados, Secretaria Estadual de Saúde do Maranhão, São Luís 65010-650, Brazil.
Juliana S S MacedoFarmácia Estadual de Medicamentos Especializados, Secretaria Estadual de Saúde do Maranhão, São Luís 65010-650, Brazil.
Pedro S Carvalho JúniorFarmácia Estadual de Medicamentos Especializados, Secretaria Estadual de Saúde do Maranhão, São Luís 65010-650, Brazil.
Cristiane Silva E SilvaPrograma de Pós-Graduação, Universidade CEUMA, São Luís 65075-120, Brazil.
Mahiba M R S MartinsCentro de Especialidades Médicas Vinhais, São Luís 65075-180, Brazil.
Valério Monteiro-NetoPrograma de Pós-Graduação em Ciências da Saúde, Universidade Federal do Maranhão, São Luís 65080-805, Brazil.ORCID 0000-0003-2868-1314
Marcos A G GrisottoSpedali Civili di Brescia, DSCS-c/o U.O. Reumatologia e Immunologia Clinica, Brescia, 25123 Lombardia, Italy.ORCID 0000-0003-2077-7979
Anita M R FernandesMestrado em Computação Aplicada, Universidade do Vale do Itajaí, Itajaí, São José 88102-700, Brazil.
Juliano FerreiraDepartamento de Farmacologia, Universidade Federal de Santa Catarina, Florianópolis 88040-900, Brazil.
João B CalixtoCentro de Inovação e Ensaios Pré-Clínicos-CIEnP, Florianópolis 88056-000, Brazil.
Robinson Sabino-SilvaInstituto de Ciências Biomédicas, Universidade Federal de Uberlândia, Uberlândia 38400-902, Brazil.ORCID 0000-0002-2104-5780
Elizabeth S FernandesInstituto de Pesquisa Pelé Pequeno Príncipe, Curitiba 80250-060, Brazil.ORCID 0000-0002-0567-2514

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 305676/2019-9 and 408053/2018-6Coordenação de Aperfeiçoamento de Pessoal de Nível Superior Finance code 001Fundação de Amparo à Pesquisa do Estado de Minas Gerais Finance code 001INCT-INOVAMED 465430/2014-7INCT-TeraNano 465669/2014-0
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a painful inflammatory disease of the joints which affects a considerable proportion of the world population, mostly women. If not adequately treated, RA patients can become permanently disabled. Importantly, not all the patients respond to the available anti-rheumatic therapies, which also present diverse side effects. In this context, monitoring of treatment response is pivotal to avoid unnecessary side effects and costs towards an ineffective therapy. Herein, we performed a pilot study to investigate the potential use of flow cytometry and attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy as measures to identify responders and non-responders to leflunomide, a disease-modifying drug used in the treatment of RA patients. The evaluation of peripheral blood CD62L

Indexed as

ATR-FTIRleflunomideperipheral blood cellsrheumatoid arthritistreatment response

Identifiers

PMID33573015
PMCPMC7910893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.